期刊文献+

血浆NT-proBNP对急性呼吸困难鉴别意义 被引量:2

Significance of Plasma NT-proBNP in Identification of Acute Dyspnea Patients
下载PDF
导出
摘要 目的探讨N末端脑钠肽前体(NT-proBNP)对心源性呼吸困难和肺源性呼吸困难的鉴别价值。方法选择2010年3月~2011年12月住院的呼吸困难患者88例,根据呼吸困难的病因不同,分为心源性组和肺源性组,同时选择健康体检者40名为正常对照组,检测三组血浆NT-proBNP水平,采用超声心动图检测心肺两组患者的左室射血分数、左室舒张末内径、左房舒张末内径。结果心源性组NT-proBNP水平与肺源性组比较,差异有统计学意义(P〈0.05),心源性组、肺源性组NT-proBNP水平分别与对照组比较,差异均有统计学意义(均P〈0.05)。心源性组左室射血分数和肺源性组比较,差异有统计学意义(P〈0.05)。结论NT-proBNP可作为鉴别心源性呼吸困难和肺源性呼吸困难的一个客观指标,较BNP稳定、可靠,同样可广泛应用于心衰的诊断和危险分层。 Objective To investigate the value of NT-proBNP in the differential diagnosis of dyspnea caused by heart disease or pulmonary disease.Methods 88 cases of patients with dyspnea were selected from March 2010 to December 2011 according to the cause of dyspnea,the patients were divided into cardiogenic group and pulmonary group.40 healthy cases were selected simultaneously.The levels of NT-proBNP in three groups were detected,and left ventricular ejection fraction were detected by echocardiography in cardiogenic group and pulmonary group.Results The level of NT-proBNP in cardiogenic group compared with pulmonary group,there was a significant difference(P 〈 0.05);the level of NT-proBNP in card!ogenic group and pulmonary group compared with control group respectively, there were significant differences(all P 〈 0.05);the left ventricular ejection fraction in cardiogenic group compared with pulmonary group,there was a significant difference(P 〈 0.05).Conclusion NT-proBNP can be used as an objective indicator to identify cardiac dyspnea and pulmonary breathing difficulties,compared with BNP, stable and reliable;the same can be widely used in the diagnosis and risk stratification of heart failure.
出处 《中国血液流变学杂志》 CAS 2012年第3期419-421,共3页 Chinese Journal of Hemorheology
关键词 呼吸困难 心衰 N末端脑钠肽前体 鉴别诊断 dyspnea heart failure NT-proBNP differential diagnosis
  • 相关文献

参考文献8

  • 1Januzzi JL,van Kimmenade R,Lainchbury J,et al.NT- proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure:an international pooled analysis of 1256 patients:the International Collaborative of NT-proBNP Study[J].Eur Heart J,2006,27(3):330 - 337.
  • 2Sudoh T, Kangawa K,Minamino N,et al.A new natriuretic peptide in porcine brain[J].Nature, 1988,332(6159): 78 - 81.
  • 3Hunt PJ,Espiner EA,Nicholls MG,et al.The role of the circulation in processing pro-brain natriuretic peptide(proBNP) to amino-terminal BNP and BNP-32[J]. Peptides,1997,18(10):1475- 1481.
  • 4Wendelboe Nielsen O,Kirk V, Bay M,et al.Value of N-terminal pro brain natriuretic peptide in the elderly:data from the prospective Copenhagen Hospital Heart Failure study(CHHF)[J].Eur J Heart Fail,2004,6(3):275 - 279.
  • 5Bay M,Kirk V, Pamer J,et al.NT-proBNP:a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function[J]. Heart,2003,89(2):150 - 154.
  • 6陈协兴,洪华山,王一波,江琼,陈良龙.脑钠素在慢性心力衰竭诊断、预后评估中的价值[J].中国循环杂志,2003,18(6):434-436. 被引量:17
  • 7史晓敏,林箐,徐国宾,宋以信,夏铁安.血清N末端B型钠尿肽原在心功能评价及慢性充血性心力衰竭诊断中的初步应用[J].中华检验医学杂志,2005,28(1):37-41. 被引量:77
  • 8Dickstein K,Cohen-Solal A,Filippatos G,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.Dveloped in collaboration with the Heart Failure Association of the ESC(HFA) and endorsed by the European Society of Intensive Care Medicine(ESICM)[J].Eur Heart J,2008,29(19):2388 - 2442.

二级参考文献18

  • 1史晓敏,宋以信,徐国宾,夏铁安.人血清N端脑钠肽水平参考值范围及其测定稳定性的初步调查[J].中国实验诊断学,2004,8(5):451-455. 被引量:18
  • 2[1]Maeda K,Tsutamota T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J,1998,135 : 825-832.
  • 3[2]Maisel AS,Krishnaswamy P, Richards M, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med, 2002,347:161-167.
  • 4[3]Mcdonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet, 1998,351:9-13.
  • 5[5]Suzuki T, Yamaoki K, Nakajima O, et al. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels . Jpn Heart J, 2000,41: 205-214.
  • 6[6]Cowie MW.BNP: soon to become a routine measure in the care of patients with heart failure? Heart,2000,83:617-618.
  • 7[7]Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med, 2002, 39: 131-138.
  • 8[8]Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriureric peptide in cardiology.J Lab Clin Med, 1999, 134:437-444.
  • 9Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol, 1997, 47:287 -296.
  • 10Yeo KT , Wu AH , Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta, 2003, 338:107-115.

共引文献92

同被引文献25

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部